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Background. Despite controversy, bipolar disorder (BD) is being increasingly diagnosed in under 18s. There is scant information
regarding its treatment and uncertainty regarding the status of “severe mood dysregulation (SMD)” and how it overlaps with
BD. This article collates available research on treatment of BD in under 18s and explores the status of SMD. Methods. Literature
on treatment of BD in under 18s and on SMD were identiﬁed using major search engines; these were then collated and re-
viewed. Results. Some markers have been proposed to diﬀerentiate BD from disruptive behaviour disorders (DBD) in children.
Pharmacotherapy restricted to short-term trials of mood-stabilizers and atypical-antipsychotics show mixed results. Data on
maintenance treatment and non-pharmacological interventions are scant. It is unclear whether SMD is an independent disorder
oranearlymanifestationofanotherdisorder.Conclusions.Valproate,lithium,risperidone,olanzapine,aripiprazoleandquetiapine
remain ﬁrst line treatments for acute episodes in the under 18s with BD. Their eﬃcacy in maintenance treatment remains unclear.
ThereisnovalidatedtreatmentforSMD.ItislikelythatsomechildrenwhoarecurrentlydiagnosedwithBDandDBDandpossibly
most children currently diagnosed with SMD will be subsumed under the proposed category in the DSM V of disruptive mood
dysregulation disorder with dysphoria.
1.Introduction
Apopularmythinpsychiatrywasthatbipolardisorderiseas-
ily recognisable with clear episodes of mania and depression
interspersed with lengthy periods of normal functioning.
And that even when it onsets in children and adolescents it
is straightforward to diagnose and can be treated with the
same concoction of mood stabilizers and antipsychotics that
“cures or controls” adults with bipolar disorder (BD). This
myth has been decimated by the mountain of literature that
has accumulated on paediatric bipolar disorder (PBD) over
the last two decades. Much has been written about the dif-
ﬁculties and controversies surrounding its presentation and
diagnosis, including whether DSM IV criteria can be reliably
applied to diagnose children with bipolar disorder, whether
irritability rather than euphoria is the predominant mood
state and whether these outbursts of pathological mood
states fulﬁl the required duration criteria. The reported high
rates of comorbidity of attention-deﬁcit hyperactivity dis-
order (ADHD) and disruptive behaviour disorders (DBDs)
with PBD are another contentious area [1–4]. Evidence is
beginningtoemergeonthelongitudinalcourseofPBDwhen
it onsets in childhood or adolescence. Recent methodologi-
cally sound studies endorse childhood onset bipolar disorder
as a relapsing disorder enduring into adulthood [5–7]: little,
however, is known with regards to management of these
children. Most treatment trials assume that all children with
PBD present with an acute manic episode and should be
treated as such. Consequently the majority of evidence is
for time-limited pharmacotherapy in adolescents [8]. There
are gaps in our knowledge in how to treat younger children
with BD and in eﬀective psychological and social forms of2 Depression Research and Treatment
treatment. A thorough examination of this question is not
complete without devoting some attention to children with
“severe mood dysregulation” (SMD) who at face value seem
to share a lot of characteristics with BD not otherwise spec-
iﬁed (BD NOS), and to see what works for them. Diﬀerent
research groups have had diﬀerent deﬁnitions for BD NOS,
and consequently these have diﬀerent conversion rates to BD
[4]. Recent research also suggests a lower conversion rate of
SMD to the classic bipolar phenotype when compared to
the narrow phenotype bipolar disorder in the longitudinal
course [9]. Perhaps the solution to the PBD puzzle lies in the
amalgamation of psychosocial and pharmacological strate-
gies that can eﬀectively “control” this disorder so that its
impact on normal development can be limited and positive
health promoted. This paper will ﬁrst brieﬂy examine diag-
nostic issues and information on the course and outcome of
PBD, followed by a synopsis on the current status of “severe
mood dysregulation” as an entity. We will then examine the
current evidence with regards to both pharmacotherapy and
psychosocial management of both PBD and SMD.
2. Methods
AsearchwasconductedusingPubMed,Embase,andPsychlit
from 1990 through 2011 using the search terms pediatric
bipolar disorder, mania, children, treatment, antipsychotics,
mood stabilizers,a n dsevere mood dysregulation. The search
was limited to clinical trials published in the English
language. Weight-age was given to articles based on its type
(review, original research, meta-analysis), its source of fund-
ing and kind of study (open trial, double blind trial, whether
randomized control or not), and recency. The references of
all recent review articles on pediatric bipolar disorder were
reviewed manually to limit studies being missed. Some non-
published studies which were presented in conferences were
quoted in view of their importance. Older studies of lithium
in PBD were included owing to limited recent data. The
identiﬁed articles were reviewed by the three authors of the
study and the results collated.
3. Diagnosisof PaediatricBipolar Disorder
Breaking free of existential issues, the presence of BD in
children and adolescents is now accepted [10–12]. Several
aspects of it however remain controversial; for example,
“How common is it?” Few prevalence studies of BD in ado-
lescents exist and the most commonly quoted prevalence ﬁg-
ure is 1% [10, 13]. There are no known prevalence studies of
BD in prepubertal children. Diagnosis of bipolar disorder in
adolescents is subject to little controversy. However the same
issue in prepubertal children seems a diﬀerent kettle of ﬁsh
altogether. Those children and adolescents that demonstrate
traditional DSM IV or ICD 10 criteria for BD are relatively
straightforward to diagnose [14, 15]. These are the ones with
BD type I and those with BD type II who present with clear
hypomanic episodes. It is usually the other group of children
who generate diagnostic controversy. They usually have very
poor emotional regulation with signiﬁcant outbursts, poor
frustration tolerance, insecure attachments, and a learned
pattern that temper tantrums and threats succeed in getting
them what they want. Although there is a high comorbidity
with disruptive behavior disorders (DBDs), that disorder
alone does not explain all of their symptoms. These are a
diﬃcult group of children that clinicians often struggle with
anditistemptingtodismissthisgroupasnotbeingrepresen-
tative of bipolar disorder. After all, they lack the character-
istics that have long been traditionally thought to correlate
with BD including a week of mania (or four days of hypo-
mania), clear-cut episodicity with the episodes lasting weeks
or months, and good interepisode functioning. It is crucial
to diﬀerentiate manic/mixed symptoms from disruptive be-
haviordisorders,diﬃculttemperament,developmentallyap-
propriate excitement, and fantasy and those that are accen-
tuated owing to the presence of a chaotic psychosocial envi-
ronment [16, 17].
Some features whose presence would prompt a clinician
to suspect BD not otherwise speciﬁed are as follows. (i)
Onset: BD is not a developmental disorder, it is usually pos-
sible on thorough assessment involving the child and care-
givers to establish premorbid functioning and an onset of
current mood symptoms, (ii) Lack of clear precipitants: the
occurrence of severe mood episodes appears to be internally
driven rather than as a response to psychosocial precipitants,
(iii) Unpredictable and unstable mood: which is a hallmark
ofasevereaﬀectivedisorderlikeBD,(iv)Cyclesofirritability,
depression, elation and grandiosity lasting at least 4 hours—
longer than could be explained by regular temper tantrums.
In addition, these children have a chronic course with the
mooddisturbancesometimeslastingyears,theirmoodcycles
severaltimes aday,andthis type ofBDhasayoungeraverage
ageofonsetthanthemoretraditionalform.Apositivefamily
history of mood disorder is another common ﬁnding in this
group of children [7, 12]. A landmark study which has clar-
iﬁed this further is the COBY study in which a four-year fol-
lowup of 141 children with BD NOS revealed a 40% rate of
conversion to BP I or II. They concluded that subsyndromal
DSM-IV criteria may be valid to deﬁne BD NOS which is a
strong predictor of BP I or II [7].
4. Outcome of PaediatricBipolar Disorder
Available outcome studies of this group of children paint a
bleakpicture[5–7].StudiesonthecourseofBDwhichonsets
in childhood and adolescence have yielded diﬀering results.
One set of studies show it to have a classical episodic course,
with episodes lasting few months [18, 19] whereas others
have found it to be more protracted with episodes lasting
years [6, 20].
There have been ﬁve major retrospective studies over last
two decades which compared adolescent onset with adult
onset BD and found that those with adolescent onset had
longer episodes, more number of episodes, greater com-
orbidity, longer time of illness before treatment, more rapid
cycling, more suicidality, and poorer overall outcome [21–
25]. Key prospective studies of children and adolescents
with BD to date include two Indian and ﬁve American
studies which have had sample sizes ranging from 25 to over
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[6, 7, 19, 26–28]. Overall these studies found that, with
treatment, the mean index manic/mixed episode length was
10–14 weeks, 81–100% have episodic recovery, 50–80% ex-
perience one or more recurrences over a 5-year period, and
the majority of recurrences occur in the ﬁrst two years of
the index episode. In addition over the duration of the
study period, there was a switch from BP-NOS to BP I or
II disorder and from BP II to BP I and the trend was child-
adolescent-adult = BP NOS to BP I. In addition the studied
young people had high rates of hospitalisation and health
service utilization, high unemployment, legal problems, and
poor academic and psychosocial functioning. Predictors of
poor outcome included early onset, low socio-economic sta-
tus, subsyndromal mood symptoms, longer duration of ill-
ness, BP NOS (rather than types I or II), other psychiatric
comorbidities, and presence of signiﬁcant family psycho-
pathology. These ﬁndings however should not be overin-
terpreted as there have been few studies with small sample
sizes with relatively short duration of followup as compared
to adults with BD who have been followed up over a few
decades, the studies used diﬀerent methodologies and def-
initions of BD, and most studies recruited mainly BP I popu-
lation. Further, the subjects entered various studies at dif-
ferent stages of illness, and there were diﬀerent cultural and
ethnic groups [5].
5. Pharmacological Treatment of
PaediatricBipolar Disorder
Instarkcontrasttoadultresearch,thereislimiteddataonthe
treatment of bipolar disorder in children and adolescents.
Evidence is predominantly from open-label trials and few
randomized control trials (RCTs). The American Academy
of Child and Adolescent Psychiatrists came up with practice
parameters in 2007 [29] .T h e r ei ss o m ee v i d e n c ef o rt h eu s e
of mood stabilisers including lithium and anticonvulsants,
and antipsychotics (APs)—both typical and atypical in PBD
and limited data available on other treatments. The only
FDA-approved mood stabiliser for PBD is lithium (age 12
and older). FDA-approved antipsychotics are aripiprazole,
risperidone, and quetiapine to treat acute manic and mixed
episodes in BD aged 10–17 years. Olanzapine has been ap-
proved for BD aged 13–17 years. Aripiprazole was also ap-
proved for maintenance treatment in PBD aged 10–17 years.
In Australia, no psychotropic medication is approved for use
in persons under age of 18 years.
5.1. Synopsis of Key Studies on the Treatment of PBD. Kafan-
taris et al. used lithium and AP (haloperidol/risperidone)
for treating acute bipolar mania in adolescents and noted
lower relapses if the AP was maintained for at least 4 weeks
[30]. Another study attempted lithium discontinuation after
patients were acutely stabilised on lithium by randomising
to lithium or placebo. As relapse rates in both the groups
were high, a question of whether lithium is eﬃcacious over
a period of time was raised [31]. Yet another open-label
study by this group demonstrated good eﬃcacy in patients
treated with lithium but noted that many patients were also
on antipsychotics. The study did not clarify to what degree
the response could be attributed to lithium [32]. Other trials
have looked at the eﬃcacy of lithium compared to valproa-
te/placebo or lithium versus valproate/carbamazepine [33,
34]. Both these trials which were RCTs demonstrated bet-
ter results with valproate than lithium or carbamazepine.
However, a subsequent trial did not demonstrate any supe-
riority for valproate over placebo [35]. Given the good ef-
ﬁcacy in adults and the lack of strong methodologically
rigorous studies on lithium, deﬁnitive studies pertaining to
the eﬃcacy in acute and long-term treatment of PBD (the
Collaborative Lithium Trials (CoLT)) are currently in pro-
gress [36]. Furthermore, two trials of oxcarbamazapine did
not support any signiﬁcant beneﬁt [37, 38]. Biederman et al.
noted a signiﬁcant improvement in the treatment of acute
mania with Lamotrigine in a 12-week open-label trial of 39
adolescents [39]. However, this study had a higher dropout
r a t ed u et os i d ee ﬀects especially skin rash.
Based on current evidence of mood stabilizer monother-
apyforPBD,valproatehassomeevidenceincontrolledtrials,
while the evidence for lithium seems to come from open
studies. Carbamazepine did not fare well.
Two studies evaluated lithium-valproate combinations
in the acute treatment of bipolar mania or mixed states. One
showed that patients with acute PBD depression or manic
type respond to lithium-valproate combination therapy [40]
and the other showed that most youth who had been stabi-
lised on a combination therapy, who then relapsed on
monotherapy, could be restabilised on combination therapy
[41].
T h em o s tr e c e n ts t u d i e sh a v et e n d e dt oe v a l u a t eu s e
of atypical antipsychotics in the treatment of acute bipolar
mania. Pavuluri et al. compared risperidone to valproate in
66 patients and noted that risperidone was slightly faster
acting and that group tended to have a better retention rate
[42]. Another study found that quetiapine was as eﬀective as
valproate and faster acting in the acute manic phase of PBD
[43]. Wozniak et al. noted that a combination of olanzapine
and topiramate was no better than olanzapine monotherapy
for acute mania in adolescents [44].
There have been few short-duration trials with other
antipsychotics. Haas et al. noted that risperidone (0.5–
2.5mg/day) was eﬃcacious and relatively well tolerated in
the acute treatment of manic or mixed episodes in children
and adolescents in the ages of 10 to 17 years [45]. In another
RCT, 161 adolescents with an acute manic or mixed episode,
Olanzapine (2.5–20mg/d) was superior to placebo after 3
weeks[46].Delbelloetal.concludedthatquetiapine,atdoses
of 400 and 600mg/d, was more eﬀective than placebo in
treating acute manic symptoms in children and adolescents
with BD in the ages of 10 to 17 years. Although the study
duration was short (3 weeks), the sample size was large (277)
[47].Findlingetal.(102)notedthatAripiprazolwaseﬀective
in PBD (manic or mixed subtype) at doses of 10mg/day
and 30mg/day [48]. Ziprasidone (dose 80–160mg/day) was
found to be superior compared to placebo in 238 adolescents
aged 10 to 17 [49]. However, in April 2010, the FDA cited
that the drugmaker had failed to properly ensure monitoring
ofitsstudy,andasaresult,widespreadoverdosingofpatients
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a timely manner. So far, Ziprasidone has not been approved
for treatment of PBD [50].
Very few studies evaluated maintenance therapy in PBD.
Some studies have commented on the eﬃcacy of lithium
in preventing relapse [26, 51]. Findling et al. noted that
both lithium and valproate were good maintenance agents
but noted that, in both trials, symptoms returned subse-
quently in about 16 weeks [52]. Another study noted that
aripiprazole was superior to placebo at 30 weeks [53]. Supe-
riority of AP in maintenance treatment has not been demon-
strated, and increased adverse events are observed with long-
term treatment. Recommendations for MS (alone or in com-
bination with AP) will be more accurate for maintenance
therapy based on some studies; however there is still need
for more research in this ﬁeld.
Bipolar depression is probably the least studied of all the
bipolar presentations in children and adolescents. Patel et
al. found signiﬁcant improvement for treatment of bipolar
depressionwithlithiuminanopen-labelledtrial[54].Chang
et al. noted that 63% were responders for lamotrigine in
another open-label trial of paediatric depression [55]. Del-
bello et al. noted no diﬀerence in eﬃcacy between quetiapine
(300–600mg/day) and placebo in a similar sample [56]. It
is important to note that no diﬀerence was noted due to
high rates of placebo response. There is a signiﬁcant lack of
studies on treatment of bipolar depression in children and
adolescents, and more RCTs are needed to clarify the same.
In view of the vast data on the metabolic complications
of atypical AP in paediatric patients, caution would be
a d v o c a t e di nt h eu s eo fA P si nP B D[ 57]. One example
was the study by Tohen which found signiﬁcant weight gain
and metabolic abnormalities in subjects on olanzapine [46].
Increased TG and cholesterol were noted especially with
olanzapine and quetiapine and increased TG with risperi-
done and no signiﬁcant metabolic changes with aripiprazole.
Itisimportanttonotethatthemetabolicriskisheterogenous
across AP. Maximum weight gain has been reported with
olanzapine and least with aripiprazole [58, 59].
As no study has compared treatment eﬃcacy between
prepubertalandadolescentpatientswithPBD,recommenda-
tions for prepubertal patients cannot be made independent
of adolescent patients. The limited data would suggest that,
while acute mania in adolescents responds to either mood
stabilisers or antipsychotics, short-term eﬃcacy is probably
better for antipsychotics than mood stabilisers [8]. Adult
data suggest that the choice of mood stabiliser lithium ver-
s u sv a l p r o a t ew o u l dd e p e n do ns e v e r a lf a c t o r s .S o m ef a c t o r s
identiﬁed in adults with acute mania which favour a better
response to lithium are euphoric mania rather than dyspho-
ric, ﬁrst episode mania, positive family history of bipolar
disorder, positive family history of response to lithium, and
absence of medical complications or substance abuse [60].
These factors need to be validated in PBD. Current data only
supports the use of mood stabilisers for long-term main-
tenance, and the use of APs for this purpose should be
pursued cautiously. The evidence for bipolar depression is
even more limited but seems to reﬂect the adult guidelines
which suggest ﬁrst-line treatment should be lithium or lam-
otrigine [61].
6. Psychosocial Management of
PaediatricBipolar Disorder
Traditionally psychosocial interventions for PBD have fo-
cussedonpsychoeducationoftheillness,augmenting coping
skills, and implementation of strategies to maximise med-
ication compliance. As discussed earlier, the eﬀectiveness of
pharmacotherapy in returning a child with BD to premorbid
functioning is unclear. In addition there are diﬃculties with
compliance and with side eﬀects of medications which may
prevent a desired trial. As a result, there has been a renewed
interest in evaluating the eﬀectiveness of various psychoso-
cial strategies in PBD, both as adjuncts and alternatives to
pharmacotherapy and also in various stages of illness, right
from those at high risk to develop PBD through to those
w h oh a v eh a di tf o rs e v e r a ly e a r s .
The feasible interventions that have been developed and
have been received well by families in PBD include family-
focused treatment (FFT), multifamily psychoeducation
groups, interpersonal and social rhythm therapy (IPSRT),
Cognitive Behavioural Therapy (CBT), and Dialectical Be-
havioural Therapy (DBT) [62].
Family-focussed therapy and multifamily psycho-educa-
tion groups have demonstrated eﬃcacy in alleviating mood
symptoms,preventingrecurrences,andenhancingpsychoso-
cial functioning in PBD. In addition, youth at high risk for
BDincludingthosewithSMDhaveshownsomebeneﬁtfrom
targeted psycho-educational therapy or behaviour modiﬁ-
cation approaches and one study found that multifamily
psychoeducation groups could exert a protective eﬀect on
conversion to BD among children with depressive spectrum
disorders[63–67].Theskill-trainingmodulesofFFTattempt
to ameliorate the impact of high-EE attitudes and behav-
iours in families, including aversive communication between
parent and oﬀspring, hostility, low family cohesion and
adaptability, and diﬃculties with conﬂict resolution [68]. A
recent study examined one-year treatment outcome trial of
an adapted version of FFT for youth (mean age 13.4yrs) who
were at high risk of developing BD-I or BD-II. These youth
showed signiﬁcant reductions in depression and hypomania
symptoms and improvements in global functioning over one
year [69]. There is consensus that psychosocial interventions
need to focus on educating about signs of early relapse,
adherence to treatment, coping strategies in interpersonal
relations, and stress management. This can be achieved by
using a combination of the above treatments. Stress manage-
ment is a big part of psychosocial intervention since stress
and trauma act as both contributing factors and as outcomes
of manic/depressive episodes. There is evidence to suggest
that young onset mania is triggered more often by stress
than adult onset [70]. While there is more evidence in adults
for the eﬃcacy of these interventions, similar outcomes are
starting to be reported in children and adolescents [71].
To date there is no data to suggest that any one form of
psychosocial intervention is better than the other and all
of them have been trialled in conjunction with pharmaco-
therapy. As with pharmacotherapy, the impact of psychoso-
cial interventions on the social and academic functioning
and quality of life of children with BD is unclear. PreventingDepression Research and Treatment 5
or minimizing the toxic and impairing eﬀects of BD early
before they become chronic or recurrent may help prevent
long-term functional disability.
7.SevereMoodDysregulation(SMD)
7.1. Concept and Controversies. Rages, irritability, or anger
outbursts which are out of proportion in both intensity and
duration to the trigger can be a feature in several psychiatric
and behavioural disorders in children and adolescents.
SMD is a label that is often applied to prepubertal children
with these rages. Other diagnoses that these children
attract include major depression, oppositional deﬁant
disorder (ODD), and attention deﬁcit hyperactivity disorder
(ADHD), Anxiety spectrum disorders and BD/PBD. SMD
shares symptoms of severe irritability and hyperarousal seen
in BD but the irritability is chronic and also the more com-
mon features of mania such as elation or grandiosity (as
described in DSM-IV) are absent. Children with SMD ex-
hibit developmentally inappropriate reactivity to negative
emotionalstimuli,suchas“outburstscharacterizedbyyelling
and/or aggression,” which occur at least 3 times a week, and
are impairing in at least 2 settings (home, school, peers). In
addition, these children experience symptoms for at least a
year without more than 2 symptom-free months. Onset is
usually before age 12 with one study claiming an average age
ofonsetof5.1years[72].TheDSM-5taskforcehasproposed
the putative category of temper dysregulation disorder with
dysphoria (TDDD) which has recently been changed to dis-
ruptive mood dysregulation disorder (DMDD) to describe
children with severe irritability, and this is likely to replace
SMD. DMDD is yet to be systematically studied but in es-
sence is trying to describe the mood symptoms seen in chil-
dren with SMD which is not described by just a diagnosis of
ODD (and ADHD). Also it seems that DMDD diagnosis is
notgoingtoincludethehyperarousalsymptomsdescribedin
children with SMD; this would be a very heterogenous group
with chronic irritability and recurrent severe temper out-
bursts. Owing to the ubiquitous nature of some of the pro-
posed criteria, this diagnosis, if it makes it to DSM V, is likely
to attract controversy [73]. The introduction of DMDD may
however reduce the possible overdiagnosis of BD.
One of the biggest controversies in child mental health in
the recent past has been the phenomenal increase in the pre-
valence ﬁgures for BD especially in the USA where a 500%
increase has been reported [74]. Whether this is a fact or an
artefact is a big debate in itself. What is relevant is wheth-
er rages or nonepisodic irritability is being diagnosed as
“bipolar”(sinceirritabilityisconsideredtobemorecommon
thantypicalelationorsadnessinearlyonsetmooddisorders)
oriftreatmentoptionssuchasantipsychoticsormoodstabil-
izers which are commonly prescribed for rages are driving a
bipolar diagnosis. Other factors to consider are antecedent
“beneﬁts”ofa“diagnosis”suchassubsidisedmedicationand
access to supportive services.
Diﬀerent research groups profess diverse views on the
concept of SMD. Leibenluft et al. suggested these children
with rages actually belong to a separate type of BD and com-
pared the various clinical features, treatment, and family
factors of these children with those with classical BD. The
label SMD was borne out this eﬀort which suggested that
they are a diﬀerent from the PBD group. Children with SMD
also exhibit ADHD- and mania-like symptoms, including 3
of the following: insomnia, intrusiveness, and pressure of
speech, ﬂight of ideas/racing thoughts, distractibility, and
psychomotor agitation. However, the severity of irritability
and the intensity of mood/anxiety symptoms are greater
in youths with SMD than those with ODD and ADHD.
Biederman et al. suggest that the “SMD group” can be just
subsumed under a combination of ADHD and ODD. How-
ever the ADHD plus ODD diagnosis fails to capture the
mood and anxiety that characterize SMD youth. Carlson
et al. suggested that it is important to recognize that a sub-
stantial proportion of children with this presentation have
a learning disorder or a pervasive developmental disorder
[75]. What contributions ODD, ADHD, and developmental
disorders including autistic spectrum disorders make to the
entity of SMD needs further study. The hope out of all of
this is the eventual homogenization of this diﬃcult-to-treat
population and the development of treatment guidelines
which can prevent the overprescription of mood stabilizers
and other medications.
Recent studies have thrown more light on SMD. It is
gettingclearernowthatthesechildrenarenotasmuchatrisk
to develop BD as once thought or as one would intuitively
presume. In fact, ADHD and depression have been more
common in follow-up studies of this population [76, 77].
Family genetic studies have suggested that kids with SMD
have family members with lower psychiatric morbidity rates
than those seen in BD, ADHD, and ODD/CD [78]. This also
points to SMD possibly being a separate entity and raises
m o r eq u e s t i o n sa b o u ti t sg e n e t i cb a s i s .
As evident from the above discussion there are several
issues about SMD that are unknown and/or unclear. With its
nosologicalstatusbecomingclearerandwithoperationalized
criteria in place one would hope to learn more about this
group in the near future.
7.2. Treatment of SMD. What is known about treatment for
SMD is mostly from expert views, clinical experience, and
limited controlled trials. So far there are no speciﬁc validated
treatments for SMD. The primary diﬃculty is in being able
to deﬁne a relatively “homogenous” population. Almost all
thedrugsusedinbipolardisordershavebeentrialledinSMD
in addition to stimulants along with conjunct psychosocial
therapies. Both lithium and divalproex sodium have shown
some promise in this population [79] with one randomized
placebo-controlled trial with lithium which showed a high
placebo response (in the run-in phase) and also no signif-
icant diﬀerence between lithium and placebo in the random-
ized patients [80]. This needs to be studied in larger con-
trolled studies. Treatment with antidepressants may need to
be considered based on evidence from follow-up studies that
major depression is a frequent outcome. We are some dis-
tance from being able to formulate treatment guidelines
for SMD. With the introduction of operationalized criteria
for DMDD and the advent of systematic studies, one
would expect more robust literature on treatment of this6 Depression Research and Treatment
challenging group of young people. However with the above
discussion it appears that mood stabilizers do not seem to
be the answer for children with SMD at this stage. It is im-
portant to tailor-make treatment for each child, use appro-
priate psychosocial interventions with active liaison with the
school and all other stakeholders before using medications,
treat ADHD appropriately, use medication like low doses
of antipsychotics if arousal is the main problem, SSRIs if
dysphoria is prominent (with careful monitoring for emerg-
ing suicidality or switch to mania), and have ongoing case
management, the utility of which cannot be overstated. The
potential risk of “creating” bipolar children with treatment
especially antidepressants has to be kept in mind before
initiating any pharmacotherapy. It is of utmost importance
to make informed clinical decisions with the family once all
these issues are discussed at length.
8. Summary
Controversy surrounding its morphology has not prevented
PBD from being diagnosed in increasing numbers [81].
Attempts at deﬁning a set of “criteria” to diﬀerentiate PBD
from disorders such as DBD and SMD are being formulated.
TheprecisemanifestationsofBDinprepubertalchildrenwill
hopefully become clearer as more data on long-term out-
come studies becomes apparent as it is this that will throw
light on the early manifestations. The available long-term
studies have been able to identify some predictors of out-
come, and it does appear that the morphology of BD be-
comes more classical as the child grows older. Diagnostic
controversy aside, treatment evidence for these children is
extremely scant. Bulk of the studies have been pharmaceu-
tical industry sponsored short-term trials of atypical antip-
sychotics and mood stabilizers. The available studies have
signiﬁcant limitations including small numbers, heterogene-
ityofsample(moststudiesofacutebipolartreatmentinclude
mania, hypomania or mixed) and short durations. Little is
known about the beneﬁts/eﬃcacy of maintenance therapy
or the acute treatment of bipolar depression. Lithium and
atypical antipsychotics such as risperidone, olanzapine, arip-
iprazole and quetiapine remain ﬁrst line treatments for acute
episodes in PBD. Although their use is advocated in main-
tenance treatment, their eﬃcacy remains unclear. Although
commonly used, evidence supporting the use of sodium val-
proate in this population is lacking. Further trials with larger
samples, longer duration, and homogeneity of diagnosis are
clearly warranted. There is also a lack of well-researched psy-
chosocial interventions for this population. Both family-fo-
cussed therapy and multifamily psycho-education appear to
show promise. This area needs particular attention as med-
icationaloneisunlikelytobesuccessfulasasoletreatmentin
this developmentally crucial time. Other factors to consider
are the presence of other comorbid psychiatric disorders, at-
tachment diﬃculties, and family dysfunction which make
diagnosis and treatment more complex.
S M De i t h e ra sas y m p t o mo ra sad i s o r d e rh a sg e n e r a t e d
recent interest. Although these children share some features
of PBD, long-term outcome seems to suggest that these chil-
dren may go on to develop depression with or without
ADHD. The worry is that all those children who do not
meet full PBD criteria are likely to receive the SMD diagnosis
which is likely to make it another ragbag category. Eﬀective
treatment for SMD is likely to involve a combination of
pharmacological and psychosocial treatment with signiﬁcant
involvement of the primary caregivers. However research to
demonstrate treatment eﬃcacy is still in its infancy. SMD
is likely to be subsumed under the broad rubric of DMDD
(DSM V) along with some of those currently diagnosed as
PBD or DBD. There are already early signs that DMDD
(previously TDDD) is not going to be without controversy
either [73, 77].
PBD and SMD represent two diagnoses along the mood
disorder spectrum that aﬀects a subgroup of children. Tools
to improve diagnoses, studies demonstrating long-term out-
come,andlongertreatmenttrialswithbothpharmacological
and psychosocial therapies are the need of the hour.
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